Logo image of MESO

MESOBLAST LTD- SPON ADR (MESO) Stock Fundamental Analysis

NASDAQ:MESO - Nasdaq - US5907174016 - ADR - Currency: USD

16.09  +1.01 (+6.7%)

After market: 16.2 +0.11 (+0.68%)

Fundamental Rating

2

Taking everything into account, MESO scores 2 out of 10 in our fundamental rating. MESO was compared to 556 industry peers in the Biotechnology industry. Both the profitability and financial health of MESO have multiple concerns. MESO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year MESO has reported negative net income.
MESO had a negative operating cash flow in the past year.
In the past 5 years MESO always reported negative net income.
In the past 5 years MESO always reported negative operating cash flow.
MESO Yearly Net Income VS EBIT VS OCF VS FCFMESO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

MESO has a better Return On Assets (-13.46%) than 82.01% of its industry peers.
MESO has a better Return On Equity (-19.07%) than 85.79% of its industry peers.
Industry RankSector Rank
ROA -13.46%
ROE -19.07%
ROIC N/A
ROA(3y)-13.06%
ROA(5y)-12.61%
ROE(3y)-17.67%
ROE(5y)-16.84%
ROIC(3y)N/A
ROIC(5y)N/A
MESO Yearly ROA, ROE, ROICMESO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5 -10 -15 -20

1.3 Margins

MESO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MESO Yearly Profit, Operating, Gross MarginsMESO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

2

2. Health

2.1 Basic Checks

MESO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MESO has more shares outstanding
The number of shares outstanding for MESO has been increased compared to 5 years ago.
Compared to 1 year ago, MESO has a worse debt to assets ratio.
MESO Yearly Shares OutstandingMESO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
MESO Yearly Total Debt VS Total AssetsMESO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 4.30 indicates that MESO is not in any danger for bankruptcy at the moment.
The Altman-Z score of MESO (4.30) is better than 75.36% of its industry peers.
MESO has a Debt/Equity ratio of 0.23. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.23, MESO is not doing good in the industry: 70.68% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Altman-Z 4.3
ROIC/WACCN/A
WACC9.48%
MESO Yearly LT Debt VS Equity VS FCFMESO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

MESO has a Current Ratio of 0.96. This is a bad value and indicates that MESO is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.96, MESO is doing worse than 88.13% of the companies in the same industry.
A Quick Ratio of 0.63 indicates that MESO may have some problems paying its short term obligations.
MESO's Quick ratio of 0.63 is on the low side compared to the rest of the industry. MESO is outperformed by 91.19% of its industry peers.
Industry RankSector Rank
Current Ratio 0.96
Quick Ratio 0.63
MESO Yearly Current Assets VS Current LiabilitesMESO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

4

3. Growth

3.1 Past

MESO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.22%, which is quite good.
MESO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -21.32%.
The Revenue for MESO have been decreasing by -18.80% on average. This is quite bad
EPS 1Y (TTM)15.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.95%
Revenue 1Y (TTM)-21.32%
Revenue growth 3Y-7.5%
Revenue growth 5Y-18.8%
Sales Q2Q%-6.85%

3.2 Future

The Earnings Per Share is expected to grow by 18.88% on average over the next years. This is quite good.
Based on estimates for the next years, MESO will show a very strong growth in Revenue. The Revenue will grow by 148.07% on average per year.
EPS Next Y-1.85%
EPS Next 2Y19.75%
EPS Next 3Y26.38%
EPS Next 5Y18.88%
Revenue Next Year153.91%
Revenue Next 2Y220.7%
Revenue Next 3Y235.1%
Revenue Next 5Y148.07%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MESO Yearly Revenue VS EstimatesMESO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
MESO Yearly EPS VS EstimatesMESO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

MESO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MESO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MESO Price Earnings VS Forward Price EarningsMESO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MESO Per share dataMESO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as MESO's earnings are expected to grow with 26.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.75%
EPS Next 3Y26.38%

More info and screens

0

5. Dividend

5.1 Amount

MESO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MESOBLAST LTD- SPON ADR

NASDAQ:MESO (7/23/2025, 8:00:00 PM)

After market: 16.2 +0.11 (+0.68%)

16.09

+1.01 (+6.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27 2025-02-27/amc
Earnings (Next)07-29 2025-07-29/amc
Inst Owners16.91%
Inst Owner Change-2.09%
Ins Owners18.01%
Ins Owner ChangeN/A
Market Cap2.04B
Analysts77.78
Price Target11.96 (-25.67%)
Short Float %2.76%
Short Ratio11.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.76%
PT rev (3m)-12.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-15.36%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 346.22
P/FCF N/A
P/OCF N/A
P/B 4.43
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.8
EYN/A
EPS(NY)-2.01
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS0.05
BVpS3.63
TBVpS-0.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.46%
ROE -19.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-13.06%
ROA(5y)-12.61%
ROE(3y)-17.67%
ROE(5y)-16.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 3.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.96
Quick Ratio 0.63
Altman-Z 4.3
F-Score3
WACC9.48%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)3.22%
Cap/Sales(5y)7.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.95%
EPS Next Y-1.85%
EPS Next 2Y19.75%
EPS Next 3Y26.38%
EPS Next 5Y18.88%
Revenue 1Y (TTM)-21.32%
Revenue growth 3Y-7.5%
Revenue growth 5Y-18.8%
Sales Q2Q%-6.85%
Revenue Next Year153.91%
Revenue Next 2Y220.7%
Revenue Next 3Y235.1%
Revenue Next 5Y148.07%
EBIT growth 1Y-6.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.97%
EBIT Next 3Y77.21%
EBIT Next 5YN/A
FCF growth 1Y29.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.22%
OCF growth 3YN/A
OCF growth 5YN/A